ABT-751
Based on 1 Customer Validation
ABT-751 (E7010) is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer.
For research use only. We do not sell to patients.
- Purity : 98.74%
- CAS No.: 141430-65-1
- Formula: C18H17N3O4S
- Molecular Weight:371.41
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
0.17 μM
Compound: 2, ABT-751
|
Cytotoxicity against human A2780 cells after 48 to 72 hrs by WAT-1 assay
Cytotoxicity against human A2780 cells after 48 to 72 hrs by WAT-1 assay
|
[PMID: 21126027] |
| A549 | GI50 |
1.31 μM
Compound: 2; E7010
|
Growth inhibition of human A549 cells after 48 hrs by SRB assay
Growth inhibition of human A549 cells after 48 hrs by SRB assay
|
[PMID: 28400235] |
| A549 | GI50 |
1.31 μM
Compound: E7010
|
Antiproliferative activity against human A549 cells assessed as growth inhibition after 24 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as growth inhibition after 24 hrs by SRB assay
|
[PMID: 25468039] |
| A549 | GI50 |
1.8 μM
Compound: 4; E7010
|
Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 27515320] |
| A549 | GI50 |
5.33 μM
Compound: 4, ABT-751
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 26241032] |
| A549 | IC50 |
1.31 μM
Compound: 1, E7010
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 24835786] |
| A549 | IC50 |
1.31 μM
Compound: ABT-751
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197] |
| A549 | IC50 |
1.376 μM
Compound: ABT-751
|
Antiproliferative activity against human A549 cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human A549 cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
| A549 | IC50 |
1.62 μM
Compound: 11; ABT-751
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 33479639] |
| ACHN | IC50 |
2.13 μM
Compound: 1, E7010
|
Cytotoxicity against human ACHN cells after 48 hrs by MTT assay
Cytotoxicity against human ACHN cells after 48 hrs by MTT assay
|
[PMID: 24835786] |
| ASPC1 | GI50 |
4.11 μM
Compound: 4, ABT-751
|
Cytotoxicity against human AsPC1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against human AsPC1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 26241032] |
| BT-474 | IC50 |
8.39 μM
Compound: ABT-751
|
Antiproliferative activity against human BT-474 cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human BT-474 cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
| DU-145 | GI50 |
1.2 μM
Compound: 4; E7010
|
Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 27515320] |
| DU-145 | GI50 |
1.81 μM
Compound: 2; E7010
|
Growth inhibition of human DU145 cells after 48 hrs by SRB assay
Growth inhibition of human DU145 cells after 48 hrs by SRB assay
|
[PMID: 28400235] |
| DU-145 | GI50 |
1.81 μM
Compound: E7010
|
Antiproliferative activity against human DU145 cells assessed as growth inhibition after 24 hrs by SRB assay
Antiproliferative activity against human DU145 cells assessed as growth inhibition after 24 hrs by SRB assay
|
[PMID: 25468039] |
| DU-145 | IC50 |
1.31 μM
Compound: ABT-751
|
Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197] |
| DU-145 | IC50 |
1.81 μM
Compound: 1, E7010
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 24835786] |
| HCCLM3 | IC50 |
0.671 μM
Compound: ABT-751
|
Antiproliferative activity against human HCCLM3 cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human HCCLM3 cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
| HCT-116 | IC50 |
0.9 μM
Compound: 2
|
Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 cell line
Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 cell line
|
[PMID: 12383017] |
| HCT-116 | IC50 |
0.96 μM
Compound: 2
|
Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 -C1cell line
Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 -C1cell line
|
[PMID: 12383017] |
| HCT-15 | IC50 |
340 nM
Compound: E-7010
|
Antiproliferative activity against human colon carcinoma HCT-15 cell line(MDR(-))
Antiproliferative activity against human colon carcinoma HCT-15 cell line(MDR(-))
|
[PMID: 11425534] |
| HEK293 | IC50 |
1.31 μM
Compound: ABT-751
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197] |
| HeLa | GI50 |
4.8 μM
Compound: 4; E7010
|
Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
|
[PMID: 27515320] |
| HeLa | IC50 |
0.27 μM
Compound: 2, ABT-751
|
Cytotoxicity against human HeLa cells after 48 to 72 hrs by WAT-1 assay
Cytotoxicity against human HeLa cells after 48 to 72 hrs by WAT-1 assay
|
[PMID: 21126027] |
| HeLa | IC50 |
0.355 μM
Compound: 5; ABT-751
|
Growth inhibition of human HeLa cells incubated for 72 hrs by MTT assay
Growth inhibition of human HeLa cells incubated for 72 hrs by MTT assay
|
[PMID: 27172319] |
| HeLa | IC50 |
2.18 μM
Compound: 11; ABT-751
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 33479639] |
| HeLa | IC50 |
388 nM
Compound: ABT-751
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by XTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by XTT assay
|
[PMID: 33328100] |
| Hep 3B2 | GI50 |
0.84 μM
Compound: 4, ABT-751
|
Cytotoxicity against human Hep3B cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against human Hep3B cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 26241032] |
| HepG2 | GI50 |
2.8 μM
Compound: 4; E7010
|
Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 27515320] |
| HepG2 | IC50 |
0.447 μM
Compound: 5; ABT-751
|
Growth inhibition of human HepG2 cells incubated for 72 hrs by MTT assay
Growth inhibition of human HepG2 cells incubated for 72 hrs by MTT assay
|
[PMID: 27172319] |
| HL-60 | IC50 |
0.2 μM
Compound: 2; E7010
|
Cytotoxicity against human HL60 cells assessed as inhibition of cell growth after 3 days by MTT assay
Cytotoxicity against human HL60 cells assessed as inhibition of cell growth after 3 days by MTT assay
|
[PMID: 27397495] |
| HL-60 | IC50 |
0.34 μM
Compound: E7010
|
Antiproliferative activity against human HL60 cells
Antiproliferative activity against human HL60 cells
|
[PMID: 17276056] |
| HT-29 | IC50 |
0.21 μM
Compound: 1; ABT-751
|
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay
|
[PMID: 27538123] |
| HT-29 | IC50 |
0.21 μM
Compound: E-7010
|
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 23202849] |
| HT-29 | IC50 |
1.31 μM
Compound: ABT-751
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197] |
| HT-29 | IC50 |
1.62 μM
Compound: 1, E7010
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 24835786] |
| HT-29 | IC50 |
338.7 nM
Compound: 5, ABT751
|
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
|
[PMID: 24106982] |
| HT-29 | IC50 |
514 nM
Compound: ABT-751
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by XTT assay
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by XTT assay
|
[PMID: 33328100] |
| HUVEC | IC50 |
9.2 μM
Compound: ABT-751
|
Cytotoxicity against human HUVEC cells assessed as inhibition of cell proliferation measured after 24 hrs by MTS assay
Cytotoxicity against human HUVEC cells assessed as inhibition of cell proliferation measured after 24 hrs by MTS assay
|
[PMID: 33360794] |
| Jurkat | IC50 |
0.16 μM
Compound: 2, ABT-751
|
Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
|
[PMID: 21126027] |
| KB | GI50 |
0.801 μM
Compound: 12; ABT-751, E7010
|
Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay
Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay
|
[PMID: 32171161] |
| KB | IC50 |
0.29 μg/mL
Compound: E7010
|
In vitro antiproliferative activity (4 ug/mL) was measured against KB cancer cell line using MTT colorimetric assay
In vitro antiproliferative activity (4 ug/mL) was measured against KB cancer cell line using MTT colorimetric assay
|
[PMID: 10866386] |
| KB | IC50 |
0.29 μg/mL
Compound: 5
|
In vitro inhibitory activity against KB (human carcinoma of the nasopharynx) cell proliferation.
In vitro inhibitory activity against KB (human carcinoma of the nasopharynx) cell proliferation.
|
[PMID: 1619621] |
| KB | IC50 |
0.29 μg/mL
Compound: E7010
|
Antiproliferative activity against KB human nasopharynx carcinoma in vitro
Antiproliferative activity against KB human nasopharynx carcinoma in vitro
|
[PMID: 10508428] |
| KB | IC50 |
250 nM
Compound: 1; ABT751
|
Growth inhibition of human KB cells after 48 hrs by SRB assay
Growth inhibition of human KB cells after 48 hrs by SRB assay
|
[PMID: 30476825] |
| KB | IC50 |
251.3 nM
Compound: 5, ABT751
|
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
|
[PMID: 24106982] |
| MC-38 | IC50 |
0.38 μg/mL
Compound: E7010
|
In vitro antiproliferative activity (4 ug/mL) was measured against colon 38 cancer cell line using MTT colorimetric assay
In vitro antiproliferative activity (4 ug/mL) was measured against colon 38 cancer cell line using MTT colorimetric assay
|
[PMID: 10866386] |
| MC-38 | IC50 |
0.38 μg/mL
Compound: 5
|
In vitro inhibitory activity against colon 38 cell proliferation
In vitro inhibitory activity against colon 38 cell proliferation
|
[PMID: 1619621] |
| MC-38 | IC50 |
0.38 μg/mL
Compound: E7010
|
In vitro antiproliferative activity against colon 38 murine adenocarcinoma
In vitro antiproliferative activity against colon 38 murine adenocarcinoma
|
[PMID: 10508428] |
| MCF7 | GI50 |
1.25 μM
Compound: E7010
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by SRB assay
|
[PMID: 25468039] |
| MCF7 | GI50 |
1.53 μM
Compound: 2; E7010
|
Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 28400235] |
| MCF7 | IC50 |
1.25 μM
Compound: 1, E7010
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 24835786] |
| MCF7 | IC50 |
3.79 μM
Compound: 5; ABT-751
|
Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay
Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay
|
[PMID: 27172319] |
| MKN-45 | IC50 |
166 nM
Compound: 5, ABT751
|
Cytotoxicity against human MKN45 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
Cytotoxicity against human MKN45 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
|
[PMID: 24106982] |
| MKN-45 | IC50 |
170 nM
Compound: 1; ABT751
|
Growth inhibition of human MKN45 cells after 48 hrs by SRB assay
Growth inhibition of human MKN45 cells after 48 hrs by SRB assay
|
[PMID: 30476825] |
| MRC5 | GI50 |
>100 μM
Compound: 2; E7010
|
Growth inhibition of human MRC5 cells after 48 hrs by SRB assay
Growth inhibition of human MRC5 cells after 48 hrs by SRB assay
|
[PMID: 28400235] |
| NCI/ADR-RES | IC50 |
0.29 μM
Compound: 2, ABT-751
|
Cytotoxicity against human NCI-ADR-RES expressing MDR1 cells after 48 to 72 hrs by WAT-1 assay
Cytotoxicity against human NCI-ADR-RES expressing MDR1 cells after 48 to 72 hrs by WAT-1 assay
|
[PMID: 21126027] |
| NCI-H460 | IC50 |
2.036 μM
Compound: ABT-751
|
Antiproliferative activity against human NCI-H460 cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human NCI-H460 cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
| NCI-H460 | IC50 |
217.7 nM
Compound: 5, ABT751
|
Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
|
[PMID: 24106982] |
| NCI-H460 | IC50 |
350 nM
Compound: E-7010
|
Antiproliferative activity against human lung carcinoma NCI-H460 cell line (MDR(+))
Antiproliferative activity against human lung carcinoma NCI-H460 cell line (MDR(+))
|
[PMID: 11425534] |
| NSCLC | IC50 |
1.5 μM
Compound: ABT-751; E 7010
|
Anticancer activity against human NSCLC cells
Anticancer activity against human NSCLC cells
|
[PMID: 32324396] |
| P338 | IC50 |
0.16 μM
Compound: 2; E7010
|
Cytotoxicity against mouse P338 cells assessed as inhibition of cell growth after 3 days by MTT assay
Cytotoxicity against mouse P338 cells assessed as inhibition of cell growth after 3 days by MTT assay
|
[PMID: 27397495] |
| P388 | IC50 |
0.19 μM
Compound: 2
|
Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388 cell line
Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388 cell line
|
[PMID: 12383017] |
| P388 | IC50 |
0.32 μg/mL
Compound: E7010
|
In vitro antiproliferative activity (4 ug/mL) was measured against P388 cancer cell line using MTT colorimetric assay
In vitro antiproliferative activity (4 ug/mL) was measured against P388 cancer cell line using MTT colorimetric assay
|
[PMID: 10866386] |
| P388 | IC50 |
0.32 μg/mL
Compound: E7010
|
Antiproliferative activity against P388 murine leukemia in vitro
Antiproliferative activity against P388 murine leukemia in vitro
|
[PMID: 10508428] |
| P388 | IC50 |
15 μM
Compound: 2
|
Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388/4.0 r-M cell line
Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388/4.0 r-M cell line
|
[PMID: 12383017] |
| PANC-1 | IC50 |
0.837 μM
Compound: ABT-751
|
Antiproliferative activity against human PANC-1 cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human PANC-1 cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
| PC-3 | GI50 |
0.62 μM
Compound: 4, ABT-751
|
Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 26241032] |
| PC-3 | IC50 |
0.46 μM
Compound: 5; ABT-751
|
Growth inhibition of human PC3 cells incubated for 72 hrs by MTT assay
Growth inhibition of human PC3 cells incubated for 72 hrs by MTT assay
|
[PMID: 27172319] |
| PLC-PRF-5 | IC50 |
0.792 μM
Compound: ABT-751
|
Antiproliferative activity against human PLC-PRF-5 cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human PLC-PRF-5 cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
| RKO | IC50 |
0.633 μM
Compound: ABT-751
|
Antiproliferative activity against human RKO cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human RKO cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
| SGC-7901 | IC50 |
0.738 μM
Compound: ABT-751
|
Antiproliferative activity against human SGC-7901 cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human SGC-7901 cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
| SK-BR-3 | IC50 |
0.143 μM
Compound: ABT-751
|
Antiproliferative activity against human SK-BR-3 cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human SK-BR-3 cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
| SK-BR-3 | IC50 |
0.74 μM
Compound: ABT-751
|
Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay
Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay
|
[PMID: 22850214] |
| SW480 | IC50 |
3.421 μM
Compound: ABT-751
|
Antiproliferative activity against human SW480 cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human SW480 cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
| SW-620 | IC50 |
0.19 μM
Compound: 2, ABT-751
|
Cytotoxicity against human SW620 cells after 48 to 72 hrs by WAT-1 assay
Cytotoxicity against human SW620 cells after 48 to 72 hrs by WAT-1 assay
|
[PMID: 21126027] |
| SW-620 | IC50 |
2.787 μM
Compound: ABT-751
|
Antiproliferative activity against human SW-620 cells assessed as cell viability measured after 72 hrs by MTS method
Antiproliferative activity against human SW-620 cells assessed as cell viability measured after 72 hrs by MTS method
|
[PMID: 33360794] |
In Vitro
ABT-751 (2 μM; 4, 8, 24h) can disrupt mitosis, disrupt mitochondrial membrane potential, induce ROS generation and DNA damage in hepatocellular carcinoma-derived Hep-3B cells [6].
ABT-751 (2 μM; 4, 8, 24h) can cause DNA damage in Hep-3B cells, inhibit cell proliferation and induce G2/M cell cycle arrest [6].
ABT-751 (2 μM; 4, 8, 24h) induces autophagy in TP53-deficient Hep-3B cells by inhibiting the AKT/MTOR signaling pathway, and induces apoptosis through Caspase-dependent, exogenous, and endogenous pathways. Exogenous expression of TP53 gene further increased the autophagy and apoptosis of these cells induced by ABT-751 [6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:
-
Concentration:
-
Incubation Time:
-
Result:
In Vivo
ABT-751 (100 mg/kg/day, Oral gavage (p.o.), 5 days on, 5 days off x2) has a synergistic effect on Docetaxel (HY-B0011) in prostate, NSCLC, and breast tumor xenografts in mice. Improve the inhibitory effect on tumor[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:xenograft models of neuroblastoma, osteosarcoma, Ewing sarcoma rhabdomyosarcoma, medulloblastoma and eight kidney cancer lines (six Wilms tumors, two rhabdoid)[7]
-
Dosage:100 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Had obvious inhibitory effect in neuroblastoma model.
Induced significant reduction or regression of tumor volume in rhabdomyosarcoma and nephroblastoma models.
Had a synergistic effect on vincristine or Paclitaxel (HY-B0015).
-
Animal Model:PC-3 prostate, Calu-6 NSCLC, and breast MDA-MB-468 tumor xenografts in mice[7]
-
Dosage:75, 100 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Had a synergistic effect with Docetaxel and improves the inhibitory effect on tumors.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 141430-65-1
-
Appearance Solid
-
Molecular Weight 371.41
-
Formula C18H17N3O4S
-
SMILES
COC1=CC=C(C=C1)S(=O)(NC2=C(N=CC=C2)NC3=CC=C(C=C3)O)=O
-
Synonyms
E7010
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (269.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Huang SM et al.,Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling., Nature. 2009 Oct 1;461(7264):614-20. [Content Brief]
[3]. Aggarwal C, et al. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?,Cancer Biol Ther. 2012 Mar;13(5):247-63. [Content Brief]
[4]. Silver M, Rusk A, Phillips B, Beck E, Jankowski M, Philibert J, Hahn K, Hershey E, McKeegan E, Bauch J, Krivoshik A, Khanna C.,Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.,J Vet Intern Med. 2012 Mar-Apr;26(2):349-54. doi: 10.1111/j.1939-1676.2012.00892.x. Epub 2012 Feb 28. [Content Brief]
[5]. Gaynon PS, Harned TM; for the Therapeutic Advances in Childhood LeukemiaLymphoma (TACL) Consortium. [Content Brief]
[6]. Morton CL, et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs. 2007;25(4):285-295. [Content Brief]
[8]. Yoshimatsu K, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997;57(15):3208-3213. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6924 mL | 13.4622 mL | 26.9244 mL | 67.3111 mL |
| 5 mM | 0.5385 mL | 2.6924 mL | 5.3849 mL | 13.4622 mL | |
| 10 mM | 0.2692 mL | 1.3462 mL | 2.6924 mL | 6.7311 mL | |
| 15 mM | 0.1795 mL | 0.8975 mL | 1.7950 mL | 4.4874 mL | |
| 20 mM | 0.1346 mL | 0.6731 mL | 1.3462 mL | 3.3656 mL | |
| 25 mM | 0.1077 mL | 0.5385 mL | 1.0770 mL | 2.6924 mL | |
| 30 mM | 0.0897 mL | 0.4487 mL | 0.8975 mL | 2.2437 mL | |
| 40 mM | 0.0673 mL | 0.3366 mL | 0.6731 mL | 1.6828 mL | |
| 50 mM | 0.0538 mL | 0.2692 mL | 0.5385 mL | 1.3462 mL | |
| 60 mM | 0.0449 mL | 0.2244 mL | 0.4487 mL | 1.1219 mL | |
| 80 mM | 0.0337 mL | 0.1683 mL | 0.3366 mL | 0.8414 mL | |
| 100 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.6731 mL |